Sygnis raises €18 million through new shares
This article was originally published in Scrip
Sygnis Pharma has raised €18.3 million to advance its CNS pipeline through the placement of new shares. The German biotech has sold 12,694,967 newly issued shares at €1.44 and at an exchange ratio of 9:4 to existing shareholders. As a result, Sygnis's total registered capital will increase from €28.6 million to €41.3 million. The listing of the new shares on the Frankfurt Stock exchange is expected to take place by next month and the free float of the company will decrease to about 42% on a diluted basis. In June Sygnis bought US company Amnestix for €4 million (Scrip Online, June 10th, 2008).
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.